Featured Whitepaper

Boule Diagnostics AG:
Slide preparation for WBC differential by manual microscopy

Download

Download Mobile App

Featured Video

ADLM:
ADLM 2025 – Bring the wonder to the premier global laboratory medicine conference

View Video

Partner Sites

HospiMedica

Implantable Device Could Save Diabetes Patients from Dangerously Low Blood Sugar

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

New Prostate Screening Device Could Replace Traditional Examination Method

Adaptive Spine Board to Revolutionize ER Transport

Mapping Communication Between Internal Organs to Enable Earlier Illness Diagnosis

LabCorp’s Innovative SARS-CoV-2 RNA Extraction Method Secures FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 05 Oct 2020

LabCorp Diagnostics (Burlington, NC, USA) has become the first commercial laboratory to receive an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a new, high-throughput method that uses heat and technology to extract RNA from samples collected for COVID-19 molecular testing.

The latest authorization builds on a long line of testing firsts for LabCorp as a commercial lab, such as: first FDA EUA for RT-PCR testing (March 5), first FDA EUA for at-home collection (April 20), first online consumer-initiated antibody testing, first digital service for physician-initiated patient collection (LabCorp At Home, July 7), first FDA EUA for asymptomatic testing and matrixed pool testing (July 24), and first combined test for multiple respiratory infections including COVID-19 and flu (September 8).

The latest authorization will help the company improve the speed and efficiency of RT-PCR tests, considered the ‘gold standard’ for active infections. More...

The innovative heat extraction process, which has comparable sensitivity to current extraction methods, traps viral particles, eliminating the need for RNA extraction reagents to capture and concentrate viral nucleic acid. This substantially improves testing efficiency and decreases LabCorp’s reliance on testing supplies - streamlining resources and further reducing the time needed to complete and report results for molecular tests. LabCorp has performed over 15 million molecular tests since first making the COVID-19 test available in March and is now able to process 200,000 tests per day with plans to increase capacity further.

“Innovation and scientific advancements will ultimately resolve this public health crisis,” said Marcia Eisenberg, Ph.D., chief scientific officer of LabCorp Diagnostics. “We are constantly evaluating new technologies and methods to improve the testing process, and we are excited to pioneer and introduce RNA-extraction free methodology in our laboratories, and to the diagnostic community at large.”

Related Links:
LabCorp Diagnostics

Visit expo >

Gold Member

SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test

SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Serological Pipet Controller
PIPETBOY GENIUS

New

Pan-Cancer Panel

TruSight Oncology 500

New

PSA Assay

CanAg PSA EIA

Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.

Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!